secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001213900-25-101741
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharmaceuticals updates corporate presentation; reiterates LYMPHIR Q4 2025 launch and pipeline progress
--------------------------------------------------------------------------------

- LYMPHIR (denileukin diftitox-cxdl) FDA approved for CTCL; commercial launch planned Q4 2025.
- Mino-Lok Phase 3 completed with positive topline data meeting primary and secondary endpoints.
- Halo-Lido Phase 2b completed; only prescription therapy under development for hemorrhoids.
- Citius Oncology (CTOR) spun off August 2024; CTXR intends to distribute CTOR shares to CTXR shareholders.
- Over $90M invested in LYMPHIR; new J-code (J9161) and NCCN guidelines inclusion secured.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025101741/0001213900-25-101741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025101741/ea0262321-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-101741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer